Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin lymphoma, child
Stage/Subtype:  stage III childhood anaplastic large cell lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 43 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567
Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 60
Sponsor: NCI, Other
Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2012-0506, NCI-2012-02055, NCT01701986
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: 2013-0186, NCI-2014-01025, NCT01983969
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: AAAK8060, NCT02061800
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 6 months to less than 18 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-051, 2014-002950-38, NCT02332668
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2239.00, NCI-2009-01551, 2239, P30CA015704, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 75
Sponsor: NCI, Other
Protocol IDs: 2241.00, NCI-2009-01334, P30CA015704, NCT01008462
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 65
Sponsor: Other
Protocol IDs: 2009-0266, NCI-2011-03144, NCT01010217
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: L 10,321, NYMC 525, NCT01049854
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2010-0284, NCI-2012-01889, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2206.00, NCI-2010-02222, P30CA015704, P01CA018029, NCT01251575
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: UCBT01, NCI-2011-03700, NCT01328496
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 75
Sponsor: Other
Protocol IDs: 12-016, NCT01596257
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: FT1050-03, NCT01627314
Peripheral Blood Stem Cell Transplantation Using the CliniMACS Device
Phase: Phase II
Type: Treatment
Status: Active
Age: 22 and under
Sponsor: Other
Protocol IDs: CHOP 07/216, NCT01071226
KIR Mismatched Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: HAPNK1, NCI-2013-00609, NCT01807611
Safety Study of Cord Blood Units for Stem Cell Transplants
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, NHLBI
Protocol IDs: 130116, 13-H-0116, NCT01861093
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2013-02167, COG-ANHL12P1, ANHL12P1, U10CA180886, U10CA098543, NCT01979536
Combined Cord Blood and Haploidentical Transplantation for Patients With Hematologic Malignancies
Phase: Phase II
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: HAPCORD, NCI-2014-00526, NCT02199041
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Phase: Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 9936-ALCI, ALCI, NCT00062868
Start Over